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Abstract ( 250words) 89 
Bloom’s syndrome, caused by biallelic mutations in BLM, is characterised by prenatal onset 90 
growth deficiency, short stature, an erythematous photosensitive malar rash and increased 91 
cancer predisposition. Diagnostically, a hallmark feature is the presence of increased sister 92 
chromatid exchanges (SCEs) on cytogenetic testing. Here, we describe biallelic mutations in 93 
TOP3A in ten individuals with prenatal-onset growth restriction and microcephaly. TOP3A 94 
encodes topoisomerase III alpha (TopIIIα), which binds to BLM as part of the BTRR protein 95 
complex, and promotes dissolution of double Holliday junctions arising during homologous 96 
recombination.  We also identify a homozygous truncating variant in RMI1, that encodes 97 
another component of the BTRR complex, in two individuals with microcephalic dwarfism. 98 
The TOP3A mutations substantially reduce cellular levels of TopIIIα protein and 99 
consequently subjects’ cells demonstrate elevated rates of SCE. Unresolved DNA 100 
recombination and/or replication intermediates persist into mitosis leading to chromosome 101 
segregation defects and genome instability that likely explain the growth restriction seen in 102 
these subjects and in Bloom’s syndrome. Clinical features of mitochondrial dysfunction are 103 
evident in several individuals with biallelic TOP3A mutations, consistent with the recently 104 
reported additional function of TopIIIα in mitochondrial DNA decatenation. In summary, our 105 
findings establish TOP3A mutations as an additional cause of prenatal-onset short stature 106 
with increased cytogenetic SCEs, and implicate the decatenation activity of the BTRR 107 
complex in their pathogenesis. 108 
  109 
 110 
Introduction 111 
Microcephalic primordial dwarfism (MPD) is used to collectively describe a heterogeneous 112 
group of disorders characterized by significant in utero and postnatal growth retardation 113 
alongside marked microcephaly1. Bloom’s syndrome (MIM 210900) is also associated with 114 
prenatal growth restriction, short stature and microcephaly. It is distinguished by an 115 
erythematous sun-sensitive facial rash that may become evident during childhood2. A 116 
predisposition to the development of cancer in early adulthood is also seen, with both solid 117 
tumours and haematological malignancies a major cause of early death3. Additionally, a key 118 
cytogenetic feature of Bloom’s syndrome is an increased number of sister chromatid 119 
exchanges (SCEs)4. Notably, when molecular testing is inconclusive, a finding of elevated 120 
SCEs is currently utilised for diagnostic confirmation of Bloom’s syndrome.5  121 
 In 1995, Bloom’s syndrome was shown to be caused by mutations in BLM, which 122 
encodes a RecQ family DNA helicase6. Mutations in BLM are typically biallelic loss-of-123 
function mutations7. BLM forms the BTRR protein complex with Topoisomerase III alpha 124 
(TopIIIα), and the RecQ-mediated genome instability proteins 1 and 2 (RMI1 and RMI2). 125 
Together, these proteins process double Holliday junctions (dHJ) that arise due to 126 
homologous recombination-mediated repair of dsDNA breaks during DNA synthesis8-14. The 127 
process of dHJ dissolution requires two steps. Firstly, the BTRR complex promotes the 128 
convergent branch migration of the dHJ to create a hemicatenane intermediate, and then 129 
this structure is decatenated by TopIIIα in concert with RMI1/215; 16. Dissolution of a dHJ by 130 
this mechanism can be completed without any potentially detrimental exchanges between 131 
genetic markers flanking the original site of homologous recombination. The alternative 132 
processing of dHJ by the HJ resolvases (SLX-MUS81 and GEN1 nucleases) can yield cross over 133 
events, and it is increased usage of this pathway that has been proposed to explain the 134 
increase in SCEs in BLM-deficient cells 17. Cross-over events between homologous 135 
chromosomes can lead to loss of heterozygosity (LOH)18, which can be detrimental to cell 136 
survival and contribute to increased cancer predisposition19. Additionally, unresolved 137 
recombination intermediates can persist into mitosis leading to chromosome bridges and 138 
act as a source of genome instability20.     139 
Here, we report the identification of pathogenic mutations in TOP3A in ten 140 
individuals with Bloom’s syndrome-like phenotypic features, and characterise the cellular 141 
consequences of these mutations.  142 
Material and Methods 143 
 144 
Research subjects 145 
 146 
Genomic DNA from the affected individuals and family members was extracted from 147 
peripheral blood by standard methods or obtained from saliva samples using Oragene 148 
collection kits according to the manufacturer’s instructions. Informed consent was obtained 149 
from all participating families and all procedures performed in studies involving human 150 
participants were in accordance with the Declaration of Helsinki. Research studies were 151 
approved by the Scottish Multicentre Research Ethics Committee (05/MRE00/74); the 152 
Hospital Universitario La Paz ethical committee (PI-2630); the GOSH Research Ethics 153 
Committee (09/H0706/66); the University Medical Center Göttingen Ethics Committee (Vote 154 
Ref 3/2/1) and the Institute for Genomic Medicine at Columbia University (protocol 155 
AAAO8410).  156 
Parents provided written consent for the publication of photographs of the affected 157 
individuals. For growth measurements, Z-scores (standard deviations from population mean 158 
for age and sex) were calculated using LMS growth based on British 1990 growth reference 159 
data 21. For calculation of Z-scores for growth measurements published for Bloom’s 160 
syndrome 22, full-term gestation was assumed, and post-natal growth measurements 161 
calculated from data provided for the 18-21 year age range. 162 
 163 
Exome sequencing and Sanger sequencing 164 
Exome sequencing and confirmatory capillary Sanger sequencing were performed using 165 
standard methodologies as previously published23; 24. TOP3A and RMI1 variants were 166 
annotated using NM_004618.4 and NM_024945.2 reference sequences respectively. 167 
 168 
Plasmid Construct and protein purification 169 
 170 
Cloning of the mutant hTopIIIα expression vector: A plasmid encoding the wild type TOP3A 171 
cDNA25 was modified by Quickchange XL Site directed mutagenesis kit (Agilent technologies) 172 
with the following primers to recapitulate the deletion and frame-shift present in subject 173 
P1: T3_FS_FW: 5'- CCCTCCGTCACACGACTGTGCAGAAGGA -3’ and T3_FS_RW: 5'- 174 
TCCTTCTGCACAGTCGTGTGACGGAGGG -3'.  175 
Expression and purification of TRR: The previously described plasmids encoding RMI1 and 176 
RMI214 and hTopoIIIα25  were co-transformed into E. coli Rosetta 2 cells, and the complex was 177 
expressed. The cells were disrupted in buffer A (50 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 10% 178 
glycerol, 0.1 % Igepal, 2 mM β-mercaptoethanol, 40 mM Imidazole, 1 mM PMSF, protease 179 
inhibitor tablet (PI, EDTA-free, Roche)) on ice, before dounce homogenization and sonication. 180 
After removal of cell debris by centrifugation, the lysate was affinity-purified on a 5 ml HisTrap 181 
HP affinity column. The complex was further purified on a 5 ml HiTrap Heparin HP column in 182 
buffer B (50 mM Tris-HCl, pH 7.5, 10% glycerol, 0.1 mM EDTA, 1 mM DTT) with a linear 183 
gradient of 200 mM - 1 M NaCl, followed by gel filtration on a 120 ml HiLoad 16/600 Superdex 184 
200 column in buffer B containing 200 mM NaCl. Expression and purification of the mutant 185 
TThr812LeufsTer101RR complex was performed in a similar manner. BLM was purified as described 186 
previously26 27. 187 
 188 
Double-Holliday Junction dissolution: The dHJ substrate construction and dissolution 189 
reactions were carried out as described previously15. 190 
 191 
Cell culture 192 
 193 
Dermal fibroblasts were obtained by skin punch biopsy and were maintained in amnioMAX 194 
C-100 complete medium (Life Technologies) in a 37°C incubator with 5% CO2 and 3% O2. 195 
siRNA oligonucleotides (siLUC: CUUACGCUGAGUACUUCGA, siTopIIIα SMARTpool M-005279-196 
01-0005(Dharmacon)) were transfected into dermal fibroblasts cells using RNAiMAX (Life 197 
Technologies) according to the manufacturer’s instructions.  198 
 199 
Sister Chromatid Exchange Assay 200 
Dermal fibroblasts were treated with 10 μM BrdU for 48 hrs followed by 0.5 µg/ml Colcemid 201 
for 2 hrs. Metaphases and nuclei were isolated in hypotonic buffer (0.25% KCl, 1% 202 
Na3C6H5O7), fixed with methanol:acetic acid (3:1), and dropped onto slides. Dried slides 203 
were rehydrated in PBS and then incubated with 2 µg/ml Hoescht 33342 stain in 2x SSC 204 
buffer (300mM NaCl, 30mM sodium citrate) for 15 mins. Slides were then covered in 2x SSC 205 
buffer and irradiated in UV-A at 5400 J/m2.  Dehydrated in an ethanol series and mounted in 206 
vectashield with DAPI.  207 
SCE Methodology for analysis P7,P8 : Dermal fibroblasts were treated with 26.05 µM of 208 
BrdU for 72 hrs followed by 0.5 g/mL Colcemid for 5 hrs and then harvested. Cells 209 
resuspended in a pre-warmed hypotonic solution (0.051 M KCl) for 20 min at 37 ºC, then 210 
fixed with acetic acid: methanol (1:3 vol/vol) and dropped onto slides. Samples were aged 211 
for at least 3 days, then stained with 1.56 µg/ml Hoechst 33258 (Sigma, B2883). Slides 212 
irradiated in 2xSSC with UVC (356 nm) 0.260 J/cm2, washed with 2xSSC, and stained with 213 
10% Giemsa in phosphate buffer.  214 
SCE analysis of peripheral blood samples was performed using standard methodology in a 215 
diagnostic lab setting28. 216 
Immunofluorescence and microscopy 217 
Mitotic abnormalities and G1-associated defects were analyzed as described previously29; 30. 218 
Briefly, for mitotic analysis, cells were seeded onto 22 x 22 mm glass coverslips in 6 well 219 
plates. After 18 hrs, cells were treated with 3.5 M RO3306 for 6 hrs to induce a late G2 220 
arrest, and were subsequently released into fresh media. After 45 mins, cells were fixed 221 
with 4% paraformaldehyde containing 0.2% Triton X-100 in PBS for 20 mins. For G1-222 
associated defects, RO3306 treated cells were released into fresh media for 30 mins. 223 
Prometaphase cells were shaken off and re-seeded onto poly-L-lysine coated glass slides. 224 
After 4-6 hrs, cells were fixed with 4% paraformaldehyde for 10 mins and permeabilized 225 
with 0.5% Triton X-100 for 10 mins. Fixed cells were incubated with antibodies specific for 226 
Cyclin A (Santa Cruz Biotechnology, sc-596), 53BP1 (Santa Cruz Biotechnology, sc-515841) 227 
and PICH31. 228 
 229 
Western blotting 230 
Cells were lysed in 50 mM Tris-HCl (pH 8), 280 mM NaCl, 0.5% NP40, 0.2 mM EDTA, 0.2 mM 231 
EGTA, and 10 % glycerol supplemented with protease inhibitor tablet (Roche Life Science). 232 
Protein samples were run on a 4–12 % NuPAGE Bis-Tris precast gel (Life Technologies) 233 
followed by immunoblotting using anti-TopIIIα raised against amino acids 652-1001 234 
(Proteintech, 14525-1-AP) and actin (Sigma, A2066). 235 
 236 
Results 237 
Identification of mutations in TOP3A  238 
In ongoing work to identify novel microcephalic dwarfism genes, whole exome sequencing 239 
(WES) was performed on subject P1, who had significant microcephaly and short stature (-240 
4.7 and -4.4 standard deviations (s.d.) respectively). This identified a homozygous frameshift 241 
mutation NM_004618.4: c.2718del (p.Thr907LeufsTer101) in TOP3A located on 242 
chromosome 17p11.2. Following interrogation of other cohorts and through clinical 243 
contacts made through GeneMatcher32, we subsequently ascertained a further nine 244 
individuals from seven families with biallelic deleterious TOP3A variants that had also been 245 
discovered by WES (Table 1). All variants identified were validated by Sanger capillary 246 
sequencing, and all parents were confirmed to be heterozygous carriers. Aside from the 247 
c.2718del variant (MAF 0.00041%), none of the other variants were reported in GnomAD33. 248 
Notably, four of the families from UAE, Syria and Saudi Arabia (F2, F4, F6 and F7), were 249 
homozygous for the same variant. 250 
Prenatal-onset growth restriction and microcephaly in TOP3A Individuals  251 
Prenatal growth restriction was evident, with substantially reduced birth weight in 252 
all individuals (mean weight -2.6 ± 0.9 standard deviations, s.d.) (Table 2, Figure 1A). 253 
Postnatally, both weight (mean weight -4.8 ± 1.8 s.d.), height (mean height -3.9 ±1.0 s.d.) 254 
and head circumference (mean OFC -4.0 ±1.2 s.d.) were significantly reduced. Growth 255 
parameters were similar to those previously reported for Bloom’s syndrome (mean birth 256 
weight -3.7 ± 1.2 s.d.; mean postnatal weight -3.8 ± 2.1 s.d.; mean height -3.9 ± 1.1 s.d.) 22.  257 
While multiple café-au-lait patches were present in some TOP3A individuals, the classical 258 
erythematous malar facial rash was not apparent and nor were there any reports of 259 
malignancies (although none had yet reached adulthood, Table 3, Figure 1B).  260 
Cardiomyopathy is present in some TOP3A subjects 261 
A single individual compound heterozygous for rare TOP3A variants has been 262 
reported recently with an adult-onset mitochondrial disorder (denoted as MC1 in Table 1) 263 
34. While stature was normal in this individual (adult female, 163 cm), several of the subjects 264 
reported here had clinical features that could also be attributable to mitochondrial 265 
dysfunction.  P3, P4 (family 2) had an additional diagnosis of dilated cardiomyopathy, which 266 
proved fatal in P4 at age 10. Another brother in this sibship died aged 13 of cardiomyopathy. 267 
Morphometric and other clinical information are not available for this case. In P5 (family 3), 268 
a dilated cardiomyopathy was also reported, with skeletal muscle biopsy demonstrating 269 
87% mitochondrial DNA depletion. P8 also had asymptomatic left ventricular dilatation 270 
noted on echocardiography, while P9 had hypertrophic cardiomyopathy.  271 
Given the identification of multiple individuals with biallelic deleterious variants in 272 
TOP3A, alongside a consistent clinical phenotype across the cohort, we concluded that 273 
these mutations were likely to be pathogenic. We therefore pursued confirmatory 274 
functional studies, employing both biochemical and cell biological approaches. 275 
TOP3A mutations lead to marked reduction in cellular levels of the TopIIIα enzyme 276 
Most of the identified TOP3A mutations are predicted to prematurely truncate the encoded 277 
protein (Figure 2A), and hence are likely to have significant effects on cellular protein levels.  278 
We therefore assessed the levels of TopIIIα in primary dermal fibroblast cell lines derived 279 
from P1, P7 and P8.   Immunoblotting demonstrated that the level of full-length TopIIIα 280 
protein was substantially reduced in total cell lysates from all three individuals compared to 281 
cell lines from unrelated control and parents (Figure 2B).   282 
In most subjects, the frameshift mutations would be expected to result in nonsense-283 
mediated decay of TOP3A transcripts, explaining consequent loss of TopIIIα protein. 284 
However, the homozygous frameshift mutation in P1 (p.Thr907LeufsTer101) is at the 3’ end 285 
of the gene, was not predicted to result in NMD and instead would result in a protein of 286 
similar length to the wild-type enzyme (TopIIIαThr907LeufsTer101).  The frameshift did, however, 287 
result in abolition of the C terminal zinc finger domain whose precise cellular function 288 
remains to be defined.  We therefore expressed recombinant TopIIIαThr907LeufsTer101 protein in 289 
E.coli, and purified it to homogeneity as a complex with the co-expressed RMI1 and RMI2 290 
proteins in order to characterise it further. Notably, in contrast to the TRR complex 291 
containing TopIIIαWT protein, the complex containing TopIIIαThr907LeufsTer101 protein (hereafter 292 
referred to as TopIIIαP1) exhibited reduced stability during purification, with lower yields and 293 
increased levels of degradation products evident on SDS-PAGE (Figure 2C). Nevertheless, 294 
when used in equimolar quantities to TopIIIαWT, TopIIIαP1 was proficient in a biochemical 295 
assay for double Holliday junction (dHJ) dissolution when combined with other components 296 
of the BTRR complex. This indicates that this TopIIIα variant retains a near normal level of 297 
ssDNA decatenation activity (Figure 2D-F). Therefore, we concluded that the major 298 
consequence of the TopIIIαThr907LeufsTer101 mutation, like the other truncating mutations, is 299 
severe depletion of TopIIIα enzymatic activity in cells.   300 
P5 was the only individual we identified with an amino acid substitution, p.Ala176Val, which 301 
was present in trans with a frameshift mutation.  The amino acid substitution is absent from 302 
GnomAD and in silico analyses predict the variant to be deleterious (Mutation Taster, CADD, 303 
SIFT). It is at a highly conserved residue (Figure S1) within the TOPA domain (Figure 2A), and 304 
would, therefore, be expected to be highly deleterious to enzymatic function.  305 
Given that Top3a is a developmentally essential gene in mouse35, coupled with the above 306 
results, we concluded that all the identified mutations result in marked, but most likely 307 
hypomorphic, loss of function of TopIIIα due to a reduction in the cellular level of the 308 
protein. Therefore, these mutations would be predicted to severely compromise the 309 
decatenation activity of the BTRR complex in dHJ dissolution in vivo.  To assess this 310 
possibility, we next pursued cellular assays assessing SCE frequency.  311 
SCEs are markedly elevated in TOP3A subjects  312 
dHJ can be processed by two pathways; firstly, dissolution by the BTRR complex yields non-313 
crossover products only; secondly, resolution by endonucleases that cleave HJ structures 314 
generate both non-crossovers and crossover products that are visualized as SCEs (Figure 315 
3A). To determine if dHJ dissolution is impaired in the cells of affected individuals, we 316 
assessed the frequency of SCEs. Following BrdU incorporation, we performed differential 317 
sister chromatid staining on primary fibroblasts and PHA-stimulated peripheral blood 318 
leukocytes (Figure 3B, C). TOP3A subject cells had a substantially higher number of SCEs, 319 
demonstrating a 3-6 fold increase compared to cells from controls or heterozygous parents 320 
(Figure 3C, p-value, p<0.005 for all affected individual cell lines). Therefore, excessive 321 
crossover recombination was evident in all TOP3A subjects tested, indicating that diagnostic 322 
cytogenetic assessment of SCE levels is predictive of TOP3A mutations as well as BLM 323 
mutations. 324 
Chromosome segregation defects and genome instability occur in TOP3A cells  325 
Impaired decatenation of dHJ may result in persistently entangled sister chromatids that 326 
impede chromosome segregation at mitosis20. Therefore, we performed detailed 327 
characterisation of the mitotic consequences of TopIIIα deficiency in primary fibroblasts 328 
from P1. DAPI-staining demonstrated elevated levels of chromatin bridges (Control, C=0, 329 
Parent=0.3 ± 0.4, P1=4 ± 0.6) and lagging chromatin/chromosomes (Figure 4A,B) (C=0.9 ± 330 
0.2, Parent=4 ± 0.7, P1=9.2 ± 0.9), consistent with persisting chromosome entanglements. 331 
Additionally, increased numbers of ultrafine DNA bridges were seen, revealed by 332 
immunostaining for the PICH protein on DAPI-negative regions20 (C=2.7 ± 0.3, Parent=13.1 ± 333 
1.1, P1=26.7 ± 3.8).  334 
We then examined the post-mitotic consequences of the observed chromosome 335 
segregation errors, enriching for G1 cells (Fig. 4C, D).  Micronuclei often arise from 336 
chromosome segregation errors36, and analysis of DAPI-stained cells demonstrated 337 
substantial numbers of micronucleated cells in the P1 fibroblast cell line compared to 338 
control and parental cell lines (Control=0.4 ± 0.2, Parent=1.8 ± 0.5, P1=7.5 ± 1.4).  Elevated 339 
levels of 53BP1 nuclear bodies were also seen in cyclin A-negative (G1) cells, indicative of 340 
transmission of DNA damage from one cell cycle to the next37 (Control=0.8 ± 0.3, Parent=4.5 341 
± 0.5, P1=11 ± 1.7). Taken together, we conclude that impaired dHJ decatenation in TopIIIα 342 
deficient cells results both in abnormal recombination and mitotic errors that lead to 343 
accumulation of DNA damage.  As chromatin bridges and UFBs are also present in Bloom’s 344 
syndrome individuals20 these findings are concordant with a shared disease mechanism. 345 
 A homozygous truncating variant in RMI1 associated with microcephalic dwarfism 346 
Finally, through whole exome sequencing we also identified a homozygous 347 
truncating variant in RMI1 (c.1255_1259del, p.Lys419Leufs*5) in two affected cousins (P11, 348 
P12) from a consanguineous Turkish family (F8, Table 1, Fig. S3).  Both individuals also had 349 
microcephalic dwarfism with a similar clinical phenotype and level of growth restriction as 350 
TOP3A subjects (Fig 1A, Table 2, 3). 351 
 352 
Discussion 353 
Here, we report that biallelic mutations in TOP3A cause prenatal growth restriction, 354 
microcephaly and short stature, a clinical phenotype that overlaps with that seen in Bloom’s 355 
syndrome.  Furthermore, we identify a rare RMI1 truncating variant (allele frequency, 356 
1.1x10-5) in two individuals. As no homozygous loss of function variants are reported in 357 
gnomAD, we expect this to be the cause of microcephalic dwarfism in P11 and P12. 358 
However, further case identification with other deleterious sequence variants will be 359 
necessary to establish RMI1 as a disease gene. 360 
Notably, TOP3A individuals exhibit elevated SCEs on cytogenetic testing. While cell 361 
lines were not available from P11 and P12, we also predict that increased SCE will occur in 362 
cells with the homozygous RMI1 p.Lys419Leufs*5 variant, given the important role of this 363 
protein in the BTRR complex10; 11; 38.  For many years, the diagnosis of Bloom’s syndrome 364 
rested on a demonstration of elevated SCEs, and this has continued to be employed in cases 365 
where molecular testing is inconclusive5. Hence, analysis of other BTRR components is now 366 
warranted when elevated SCEs are detected. Indeed, given the clear phenotypic overlap 367 
between Bloom’s syndrome and TOP3A individuals, re-evaluation of previous 368 
cytogenetically-diagnosed Bloom’s syndrome cases could be fruitful.  369 
RMI2 is the fourth component of the BTRR complex. A single family was recently 370 
reported with a homozygous deletion of RMI2 in which two children were also found to 371 
have elevated SCEs, with café-au lait macules evident, but mild-growth impairment evident 372 
in only one individual39. As RMI2 is not essential for BTR (BLM, TopIIIα and RMI1) enzymatic 373 
function13, a more subtle cellular and developmental phenotype might therefore result. It 374 
also remains possible that the BTR complex has functions independent of RMI2, given that 375 
BLM, TopIIIα and RMI1 are conserved in all eukaryotes but RMI2 is absent in invertebrates 376 
and yeast 14.  377 
Bloom’s syndrome is associated with predisposition to both solid tumors and 378 
haematological malignancies3. However, cancers have not been reported in our cases with 379 
TOP3A mutations. Nevertheless, all are still children and as malignancy in Bloom’s typically 380 
manifests in early adulthood, TOP3A mutations may well also confer increased risk of 381 
neoplasia. 382 
Distinct from Bloom’s syndrome, some of our TOP3A subjects have clinical features 383 
consistent with mitochondrial dysfunction, with several exhibiting a dilated 384 
cardiomyopathy. Notably, an individual with chronic progressive external ophthalmoplegia 385 
and cerebellar ataxia has been recently reported, along with a novel functional role for 386 
TopIIIα in the decatenation of mitochondrial DNA following its replication34 (in this 387 
manuscript denoted as subject, MC1). The compound heterozygous mutations c.298A>G; c. 388 
403C>T; p. Met100Val; pArg135* may have milder consequences than those reported in our 389 
cohort, and consistent with this we found that MC1 does not exhibit short stature (Table 2) 390 
or elevated numbers of SCEs in a primary fibroblast line derived from this individual (Figure 391 
S2). Thus, it appears that the residual TopIIIα activity in MC1 is sufficient for the nuclear 392 
function of the BTRR complex in dHJ dissolution and for normal growth, but may have 393 
become rate-limiting for the role of TopIIIα in mitochondrial DNA replication.  394 
Mechanistically, our cellular and biochemical studies suggest that the identified TOP3A 395 
mutations reported here are severe hypomorphs, consistent with the established essential 396 
cellular and developmental functions of TopIIIα35. Given that marked growth restriction is 397 
common to TOP3A and BLM subjects, it seems likely that they have a shared pathogenic 398 
basis arising from reduced ssDNA decatenation activity of the BTRR complex. Persistence of 399 
unresolved hemicatenanes into mitosis leads to formation of chromatin and ultra-fine 400 
mitotic bridges that have previously been reported in Bloom’s syndrome 20 and in 401 
microcephalic dwarfism individuals with condensin mutations40.  The resulting genome 402 
instability arising from persistent chromatin bridges 41; 42 and micronuclei43 may therefore 403 
impair cell viability during development, causing microcephaly and global growth restriction.  404 
In summary, we demonstrate that mutations in TOP3A cause microcephalic dwarfism with 405 
increased SCE, implicating the BTRR complex as a cause of growth disorders. 406 
 407 
Supplemental Data description 408 
Three supplementary figures and a table are provided. 409 
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 558 
Figure 1. Variants in TOP3A are associated with prenatal-onset growth retardation and 559 
microcephaly 560 
a) Morphometric data for TOP3A individuals. A global reduction in growth is evident from before birth. Z-561 
scores (standard deviations from population mean for age and sex) for birth weight (Wgt), and postnatal 562 
weight, height (Hgt) and occipital-frontal circumference (OFC). Dashed lines indicate the 95% confidence 563 
interval for the general population. Black circles, TOP3A individual data points. For comparison grey bars 564 
indicate the mean value for a cohort of n=89 (birth weight). n=47 (current weight), n=52 (current height) 565 
Bloom’s syndrome subjects22. 566 
b) Photographs of facial features of individuals with TOP3A mutations.  567 
Figure 2. Mutations in TOP3A markedly reduce levels of the TopIIIα protein but do not affect its 568 
intrinsic decatenation activity 569 
A) Schematic of TopIIIα protein with locations of variants annotated. Red, TOPRIM domain; purple TOPA 570 
domain; blue, GRF zinc finger domain.  571 
B) TOP3A mutations markedly reduce protein levels. Immunoblotting of total cell lysates from affected 572 
individual derived dermal fibroblast lines as indicated. siRNA depletion of TOP3A in control 2 fibroblast line 573 
to confirm specificity of antibody. C1 and C2 unrelated control fibroblast lines. (TopIIIα antibody raised 574 
against amino acids 652-1001). 575 
C) Recombinant TopIIIαThr812LeufsTer101 protein (denoted TopIIIαP1) is less stable than TopIIIαWT. Immunoblot of 576 
purified TopIIIαWT and TopIIIαP1 probed with TopIIIα antibody. Protein size markers 250, 170, 140, 100, 70 577 
kDa 578 
D) Schematic depicting the BTRR complex and its role in double Holliday junction (dHJ) dissolution. 579 
Homologous sister chromatids are shown in red and blue respectively.  580 
E-F) TopIIIαP1 protein is proficient for promoting dHJ dissolution with BLM in combination with the RMI1 and 581 
RMI2 proteins. E) Representative polyacrylamide gel demonstrating the enzyme concentration 582 
dependence of the dHJ dissolution activity of TopIIIαWT and mutant (TopIIIαP1) TRR complexes with 20 nM 583 
BLM at 37°C in 30 min. TRR was included in reactions at increasing concentrations ranging from 20 pM-10 584 
nM. Labelled circular oligonucleotide (lane 1) and dHJ (lane 2) were included as markers. F) Quantification 585 
of the dHJ dissolution reaction shown in panel E. The reaction was repeated two more times with very 586 
similar results. 587 
Figure 3. TOP3A individuals have elevated levels of SCEs reflecting chromatid hyper-recombination  588 
A) Schematic of dHJ processing . dHJ are either dissolved by the BTRR complex or alternatively cleaved by 589 
structure specific nucleases that lead to dHJ resolution. 590 
B-C) Elevated numbers of SCEs are evident from BrdU strand specific labelling of sister chromatids from TOP3A 591 
cells compared to control and parent cells. B) Representative images of P1 and parent fibroblast cell lines. C) 592 
Quantification of SCEs in fibroblast cell lines (P1, P5, P7, P8) or PHA-stimulated lymphocytes derived from 593 
peripheral blood samples (P2, P3). Median value plotted, n>10 metaphase spreads counted per subject. Pair-594 
wise non-parametric Mann Whitney tests versus parental controls. F1, F2 and F5 SCEs were scored in 595 
independent laboratories.  596 
Figure 4. DNA catenanes persist into mitosis in TOP3A subject cells leading to chromosome 597 
segregation defects and genome instability 598 
A-B) Chromosome segregation is impaired in TOP3A deficient primary fibroblasts. A) Representative images of 599 
chromatin bridges, lagging DNA (DAPI) and ultrafine DNA bridges (UFBs) (detected by the presence of PICH and 600 
absence of DAPI stain). B) Quantification of chromatin bridges, lagging DNA and PICH positive UFBs scored in 601 
Control, parental and P1 fibroblast mitotic cells staged at anaphase B (exp≥3, n> 50 cells, error bars = SEM). To 602 
enrich for mitotic cells, fibroblasts were treated with R03306 for 6 hrs, released and fixed after 45 min. C) 603 
TOP3A P1 fibroblast cells display significantly elevated levels of micronuclei. Top panel, representative picture 604 
of control and P1 fibroblasts. Bottom panel, Quantification of micronucleus containing interphase cells.  exp≥3, 605 
n>500, error bars = SEM. To enrich for G1 cells, RO3306 treated cells were released into fresh media for 30 606 
mins, prometaphase cells were collected, re-seeded and fixed after 4-6 hrs. D) TOP3A P1 fibroblast cells display 607 
significantly elevated numbers of 53BP1 bodies in G1 nuclei. Top panel, representative images of 53BP1 foci 608 
(red) and DNA (DAPI). Bottom panel, quantification of cells with ≥4 53BP1 foci in G1 nuclei (negative for cyclin 609 
A) (exp≥3, n>500, error bars = SEM). Scale bar = 2 microns, Two tailed t-test versus parent. 610 
 611 
612 
613 
614 
  615 
Table 1. Variants Identified in TOP3A and RMI1 associated with microcephalic dwarfism 
Family Individual Gene Biallelic Nucleotide Alterations Predicted Amino Acid Consequence(s) Sex Country of origin 
1 P1 TOP3A c.[2718del];[2718del]  p.[Thr907LeufsTer101];[Thr907LeufsTer101] Female USA (Czech/Irish ancestry) 
2 P2 TOP3A c.[2271dup];[2271dup] p.[Arg758GlnfsTer3];[Arg758GlnfsTer3] Female United Arab Emirates 
2 P3 TOP3A c.[2271dup];[2271dup] p.[Arg758GlnfsTer3];[Arg758GlnfsTer3] Female United Arab Emirates 
2 P4 TOP3A c.[2271dup];[2271dup] p.[Arg758GlnfsTer3];[Arg758GlnfsTer3] Male United Arab Emirates 
3 P5 TOP3A c.[527C>T];[1072_1073dup]a p.[Ala176Val];[Tyr359GlyfsTer17] Female Japan 
4 P6 TOP3A c.[2271dup];[2271dup] p.[Arg758GlnfsTer3];[Arg758GlnfsTer3] Female Syria 
5 P7 TOP3A c.[2428del];[2428del] p.[Ser810LeufsTer2];[Ser810LeufsTer2] Female Spain 
5 P8 TOP3A c.[2428del];[2428del] p.[Ser810LeufsTer2];[Ser810LeufsTer2] Male Spain 
     6  P9 TOP3A c.[2771dup]; c.[2771dup] p. [Arg758GlnfsTer3];[Arg758GlnfsTer3] Male Syria 
     7 P10 TOP3A c.[2771dup]; c.[2771dup] p. [Arg758GlnfsTer3];[Arg758GlnfsTer3] Female Saudi Arabia 
       
8 P11 RMI1 c.[1255_1259del];[1255_1259del] p.[Lys419LeufsTer5]; [Lys419LeufsTer5] Female Turkey 
8 P12 RMI1 c.[1255_1259del];[1255_1259del] p.[Lys419LeufsTer5] ;[Lys419LeufsTer5] Female Turkey 
Previously reported case with adult-onset mitochondrial disease 
 MC1b TOP3A c.[298A>G];[403C>T] p.[Met100Val];[Arg135Ter] Female UK 
a close to donor splice site of exon 10. b previously reported case in 34.  Nomenclature according to transcript NM_004618.4, TOP3A; NM_004618.4 and 
NM_024945.2, RMI1. 
 
 
 
 
  
Table 2. Growth parameters of TOP3A and RMI1 individuals. 
 
Pt 
 Birth Postnatal 
Gene 
mutated 
Gestn 
(weeks) 
Weight 
kg SDa 
OFC 
cm SD 
Length 
cm SD 
Age at 
Exam 
Weight 
kg SDa 
OFC 
cm SD 
Height 
cm SD 
P1 TOP3A 37 1.35 -3.9 27.5 -4.2 38 -5.4 5m 4.9 -2.7 36 -5.7 54.8 -4.4 
P2 TOP3A 37 1.9 -2.3 N/A N/A N/A N/A 3y  9.5 -3.7 47.5 -2.3 84.5 -2.8 
P3 TOP3A 37 2.2 -1.6 N/A N/A N/A N/A 8 y 16.5 -3.3 49.5 -2.9 112.5 -2.7 
P4 TOP3A 40 2.2 -2.9 N/A N/A N/A N/A 10 y 18.1 -4.6 49.5 -3.1 113 -4.1 
P5 TOP3A 35 1.91 -1.3 31.8 -0.2 43 -1.8 15 y 20 -6.4 51 -3.1 138 -3.7 
P6 TOP3A N/A 2 N/A N/A N/A N/A N/A 19 m 
mymonth
s 
5.17 -7.5 44.3 -3.0 64.3 -5.8 
P7 TOP3A 38 1.90 -2.8 30.0 -2.7 41 -4.1 3 y 3m 
months 
7.21 -7.0 44.2 -5.3 78.7 -4.7 
P8 TOP3A 34 1.41 -2.5 28.5 -2.2 42 -2.1 7 yb 10 -2.9 45.8 -5.0 98.1 -4.5 
P9 TOP3A 40 2 -3.4 N/A N/A N/A N/A 11 y  21.6 -3.5 47.5 -4.5 125.6 -2.7 
P10 TOP3A 36 1.6 -2.7 N/A N/A N/A N/A 4 y 7 m 9 -6.1 45.5 -5.0 91 -3.3 
                
P11 RMI1 34 1.59 -1.7 N/A N/A N/A N/A 7 y 14 -3.8 46.5 -5 100 -4 
P12 RMI1 38 1.80 -3.1 N/A N/A N/A N/A 13 y 39 -0.9 48 -5 135 -2.9 
 
Previously reported case with Adult onset-mitochondrial disease (ataxia, PEO)  
MC1
111 
TOP3A N/A N/A N/A N/A N/A N/A N/A adult N/A N/A N/A N/A 163 N/A 
Gestn, Gestational age. aAdjusted for gestation; b on growth hormone treatment 4 years 3 months until 5years 11 months with no response. Z-score, 
standard deviations from population mean for age and sex. y, year; m, months.   
 
  
 Table 3. Clinical phenotype of TOP3A and RMI1 subjects. 
aNote all cases <15y old, in Bloom’s syndrome, neoplasia typically early adulthood. PEO, progressive external ophthalmoplegia. CDH, Congenital dislocation of hip. 
bRecurrent otitis media and tonsillitis – tonsillectomy. cMild left ventricle dilatation.  dCombined malonic and methylmalonic aciduria (OMIM#614265) due to ACSF3 
mutations. e Expressive speech delay only. fHCM, hypertrophic cardiomyopathy.  gAnemia due to beta-thalassemia trait. hReccurent upper respiratory tract infections/oral thrush. 
  TOP3A RMI1 
Pt P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 MC1R1 P11 P12 
Age 5 m 3 y 8 y 10y 15 y 19 m 3 y 7 y 11y 4y 7m Adult 7 y 13 y 
Prenatal onset 
growth restriction 
Y Y Y Y Y Y Y Y Y Y N Y Y 
Elevated Sister 
chromatid exchange 
Y Y Y N/A Y N/A Y Y Y N/A N N/A N/A 
Café-au-lait macules Y Y Y Y N Y N Y Y Y N/A N N 
Developmental 
Delay 
Mild N N N N Milde N Mild N Mild N/A Mild N 
Cancera  N N N N N N N N N N N/A N N 
Decreased 
subcutaneous fat 
N N N N N N Y Y N Y N/A N N 
Gastrooesophageal 
reflux 
Y N/A N/A N/A N Y N N/A N N/A N/A N N 
Diabetes mellitus N N N N N N N N N N N/A N N 
Recurrent infections Yb N/A N/A N/A N N N  Y Yh N/A N N 
Malar Rash N N N N N N N N N N N/A N N 
Dilated 
Cardiomyopathy N    N Y 
Y (severe, 
deceased) 
Y (post 
heart 
transplant) 
Normal 
Echo 
N/A 
Yc 
(asymptomatic) 
HCMf N  N/A N/A 
Mitochondrial DNA 
depletion in muscle  
N/A N/A N/A N/A Y, 87%  N/A N/A  N/A N/A N/A Y, >80% N/A N/A 
Other 
CDH, 
Gastrostomy 
 
Abnormal 
movements/tics  
 
Hearing loss, 
CMMAd  
   
Microcytic 
anemiag 
 PEO, 
Ataxia 
  
  
 
